Nanoformulation innovations: Revolutionizing precision in migraine therapy

Document Type : Review Article

Authors

1 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

3 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

4 Departments of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

5 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

6 Departments of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

10.22038/ijbms.2024.79824.17290

Abstract

Objective(s): Migraine, a serious neurological disease that affects millions of people worldwide, is one of the most considerable burdens on the healthcare system and has significant economic implications. Even though various treatment methods are available, including medication, lifestyle changes, and behavioral therapy, many migraine sufferers do not receive adequate relief or experience intolerable side effects. Hence, the present review aims to evaluate the nanoformulation regarding migraine therapy.
Materials and Methods: Between 2005 and 2024, specific keywords were used to search several databases, such as Pubmed, Google Scholar, and Scopus. 
Results: The nanoformulation field is an increasing field within nanotechnology that offers new solutions for treating migraine, including improving drug delivery, increasing therapeutic efficacy, and minimizing side effects. By combining nanoscale materials with therapeutic agents, nanoformulations can enhance bioavailability, sustain drug release, deliver targeted drugs, and penetrate the Blood-Brain Barrier (BBB) more efficiently. Nanoformulation has the potential to be a useful tool for migraine therapy. However, several challenges still need to be overcome, such as the BBB penetration, safety and biocompatibility of the product, manufacturing, and scalability reproducibility to pass regulatory approval and affordability. To overcome these challenges, research efforts should be focused on developing innovative techniques to penetrate the BBB, target specific migraine pathways, incorporate personalized medicine approaches, and develop nanotechnology-based diagnostics.
Conclusion: A nanotechnology-based approach aims to revolutionize migraine therapy, improving patient outcomes and living standards by offering personalized and precise treatments. 

Keywords

Main Subjects

References

1. Gupta J, Gaurkar SS. Migraine: An underestimated neurological condition affecting billions. Cureus 2022;14:e28347.
2. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, et al. Migraine: Epidemiology and systems of care. The Lancet 2021;397:1485-1495.
3. Khan J, Al Asoom LI, Al Sunni A, Rafique N, Latif R, Al Saif S, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother 2021;139:111557. 
4. Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond Physiolog Rev 2023;103:1565-1644. 
5. Hendrix C. Migraine-Prophylactic and Acute Migraine Treatments. Evidence-Based Use of Supplements 2021;4: 1-9. 
6. Nicholson RA, Buse DC, Andrasik F, Lipton RB. Nonpharmacologic treatments for migraine and tension-type headache: how to choose and when to use. Curr Treat Option Neurol 2011;13:28-40. 
7. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus 2016;5:637-650. 
8. Society AH. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain 2019;59:1-18. 
9. Ailani J, Burch RC, Robbins MS, Society BoDotAH. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain 2021;61:1021-1039. 
10. Singh R, Brumlik C, Vaidya M, Choudhury A. A patent review on nanotechnology-based nose-to-brain drug delivery. Recent Pat Nanotechnol 2020;14:174-192. 
11. Vlieghe P, Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology‐based systems to improve CNS drug targeting and delivery. Med Res Rev 2013;33:457-516.
12. Sadr S, Lotfalizadeh N, Abbasi AM, Soleymani N, Hajjafari A, Roohbaksh Amooli Moghadam E, et al. Challenges and prospective of enhancing hydatid cyst chemotherapy by nanotechnology and the future of nanobiosensors for diagnosis. Trop Med Infect Dis 2023;8:494-515.
13. Bahadur S, Jha MK. Emerging nanoformulations for drug targeting to brain through intranasal delivery: A comprehensive review. J Drug Deliv Sci Technol 2022:103932 
14. Pandey A, Nikam A, Basavraj S, Mutalik S, Gopalan D, Kulkarni S, et al. Nose-to-brain drug delivery: Regulatory aspects, clinical trials, patents, and future perspectives.  Direct nose-to-brain drug delivery: Elsevier; 2021. p. 495-522.
15. Kumar S, Singh P, Sharma S, Pottoo FH, Ali J, Baboota S. Envisioning the future of nanomedicines in management and treatment of neurological disorders. Comb Chem High Throughput Screen 2021;24:1544-1556. 
16. Virmani R, Virmani T, Pathak K. Nanovesicles for delivery of central nervous system drugs. Applications of Nanovesicular Drug Delivery: Elsevier; 2022. 315-339. 
17. Akhtar A, Andleeb A, Waris TS, Bazzar M, Moradi A-R, Awan NR, et al. Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. J Control Release 2021;330:1152-1167. 
18. Sadr S, Poorjafari Jafroodi P, Haratizadeh MJ, Ghasemi Z, Borji H, Hajjafari A. Current status of nano‐vaccinology in veterinary medicine science. Vet Med Sci 2023;9:2294-2308. 
19. Wu D-D, Ahmed SY, Erasto NE, Zhang Y-X, Khattak S, Hussain KN, et al. Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration. Iscience 2023; 18; 26: 107321. 
20. Tanna V, Sawarkar SP, Ravikumar P. Exploring nose to brain nano delivery for effective management of migraine. Curr Drug Deliv 2023;20:144-157. 
21. Lade S, Shah N, Burle S. Nanostructured lipid carriers: A vital drug carrier for migraine treatment. Res J Pharm Technol 2022;15:3309-3016. 
22. Sachan N, Bahadur S, Sharma PK. Recent advances and novel approaches for nose to brain drug delivery for treatment of migraine. Drug Deliv Let 2019;9:182-198. 
23. Minen M, Shome A, Halpern A, Tishler L, Brennan K, Loder E, et al. A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache: J Head Face Pain 2016;56:725-740. 
24. Kesserwani H, Kesserwani HN. Migraine triggers: An overview of the pharmacology, biochemistry, atmospherics, and their effects on neural networks. Cureus 2021;13:e14243. 
25. Rapoport AM, Lin T. Device profile of the Nerivio™ for acute migraine treatment: Overview of its efficacy and safety. Exp Rev Med Dev 2019;16:1017-1023. 
26. F Gasparini C, G Sutherland H, R Griffiths L. Studies on the pathophysiology and genetic basis of migraine. Curr Genom 2013;14:300-315. 
27. Curone M, Tullo V, Didier HA, Bussone G. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients. Neurolog Sci 2022;43:5759-5761. 
28. Sudershan A, Mahajan K, Singh K, Dhar MK, Kumar P. The complexities of migraine: a debate among migraine researchers: a review. Clin Neurol Neurosurg 2022;214:107136. 
29. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults‐overview of Cochrane reviews. Cochrane Database Syst Rev 2014; 2014:CD009108. 
30. Minen MT, De Dhaem OB, Van Diest AK, Powers S, Schwedt TJ, Lipton R, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psych 2016;87:741-749. 
31. Yeh P-K, An Y-C, Hung K-S, Yang F-C. Influences of genetic and environmental factors on chronic migraine: A narrative review. Curr Pain Headache Rep 2024; 28:169-180. 
32. Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. New England J Med 2002;346:257- 270. 
33. Li Y-X, Xiao X-l, Zhong D-L, Luo L-J, Yang H, Zhou J, et al. Effectiveness and safety of acupuncture for migraine: An overview of systematic reviews. Pain Res Manag 2020; 2020:3825617. 
34. Zhang X-t, Li X-y, Zhao C, Hu Y-y, Lin Y-y, Chen H-q, et al. An overview of systematic reviews of randomized controlled trials on acupuncture treating migraine. Pain Res Manag 2019; 2019:5930627. 
35. Jan MM. Updated overview of pediatric headache and migraine. Saudi Med J 2007;28:1324-1329. 
36. Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: From pathophysiology to treatment. J Neurol 2023; 270:3654-3666. 
37. Green MW. Overview of migraine: Recognition, diagnosis, and pathophysiology. Headache Migraine Biol Manag, Elsevier; 2015. 41-9. 
38. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care 2019;25:S23-S34. 
39. Muthyala N, Qadrie Z, Suman A. Migraine & migraine management: A review. PharmaTutor 2018; 6:8-17. 
40. Ravisankar P, Hundia A, Sindhura J, Rani BS, Sai P. Migraine-A comprehensive review. J Pharma Res 2015; 5:1-20 
41. Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. New England J Med 2019; 381:2230-2241. 
42. Olla D, Sawyer J, Sommer N, Moore JB. Migraine treatment. Clin Plastic Surg 2020;47:295-303. 
43. Silberstein SD. Preventive migraine treatment. Continuum 2015;21: 973-989. 
44. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache: J Head Face Pain 2002;42:3-9. 
45. Negro A, Martelletti P. Gepants for the treatment of migraine. Exp Opin Investigat Drugs 2019;28:555-567. 
46. Tardiolo G, Bramanti P, Mazzon E. Migraine: experimental models and novel therapeutic approaches. Int J Mol Sci 2019;20:2932-2951. 
47. Alexander A, Agrawal M, Chougule MB, Saraf S, Saraf S. Nose-to-brain drug delivery: An alternative approach for effective brain drug targeting. Nanopharmaceuticals: Elsevier; 2020. 175- 200. 
48. Becker WJ. Acute migraine treatment. Continuum: Lifelong Learning in Neurology 2015;21:953-972. 
49. Pardutz A, Schoenen J. NSAIDs in the acute treatment of migraine: A review of clinical and experimental data. Pharmaceuticals 2010;3:1966-1987. 
50. Leroux E, Buchanan A, Lombard L, Loo LS, Bridge D, Rousseau B, et al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: A systematic literature review. Adv Ther 2020;37:4765-4796. 
51. Yang C-P, Liang C-S, Chang C-M, Yang C-C, Shih P-H, Yau Y-C, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Network Open 2021;4:e2128544-e. 
52. Orlova YY, Mehla S, Chua AL. Drug safety in episodic migraine management in adults part 1: Acute treatments. Curr Pain Headache Rep 2022;26:481-492. 
53. Ramachanderan R, Schramm S, Schaefer B. Migraine drugs ChemTexts. 2023;9:1-66. 
54. Konstantinos S, Vikelis M, Rapoport A. Acute care and treatment of migraine. J Neuro-Ophthalmol 2020;40:472-484. 
55. Peck J, Urits I, Zeien J, Hoebee S, Mousa M, Alattar H, et al. A comprehensive review of over-the-counter treatment for chronic migraine headaches. Curr Pain Headache Rep 2020;24:1-9. 
56. Chiang C-C, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—the monoclonal antibodies and gepants. Prog Brain Res 2020;255:143-170.
57. Maasumi K, Michael RL, Rapoport AM. CGRP and migraine: The role of blocking calcitonin gene-related peptide ligand and receptor in the management of migraine. Drugs 2018;78:913-928. 
58. Tepper SJ. History and review of anti‐calcitonin gene‐related peptide (CGRP) therapies: From translational research to treatment. Headache: J Head Face Pain 2018;58:238-275. 
59. Ray JC, Kapoor M, Stark RJ, Wang S-J, Bendtsen L, Matharu M, et al. Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects. J Neurol Neurosurgery & Psychiatry 2021;92:1325-1334. 
60. Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache: J Head Face Pain 2018;58:33-47. 
61. Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: A new era in migraine therapy. Lancet 2019; 394:1765-1774. 
62. Edvinsson L. Calcitonin gene‐related peptide (CGRP) is a key molecule released in acute migraine attacks—Successful translation of basic science to clinical practice. J Int Med 2022;292:575-586. 
63. Jackson JL, Kuriyama A, Kuwatsuka Y, Nickoloff S, Storch D, Jackson W, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019;14:e0212785. 
64. Danesh A, Gottschalk PCH. Beta-blockers for migraine prevention: A review article. Curr Treat Options Neurol 2019;21:1-13. 
65. Lai K-L, Pan L-LH, Liao K-K, Chen W-T. Electrophysiological basis for antiepileptic drugs in migraine prevention. Progress Brain Res 2020;255:69-97. 
66. Al-Karagholi MA-M, Gram C, Nielsen CAW, Ashina M. Targeting BK Ca channels in Migraine: Rationale and perspectives. CNS Drugs 2020;34:325-335. 
67. Al-Karagholi MA-M, Ghanizada H, Nielsen CAW, Skandarioon C, Snellman J, Lopez-Lopez C, et al. Opening of BKCa channels causes migraine attacks: A new downstream target for the treatment of migraine. Pain 2021;162:2512-2520. 
68. Kowalska M, Prendecki M, Piekut T, Kozubski W, Dorszewska J. Migraine: Calcium channels and glia. Int J Mol Sci 2021;22:2688-2703. 
69. Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil- Gouveia R, Jassal T, Sanchez-del-Rio M, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 2023;24:1-14. 
70. Becker WJ. Botulinum toxin in the treatment of headache. Toxins 2020;12:803-813. 
71. Marcelo R, Freund B. The efficacy of botulinum toxin in pediatric chronic migraine: a literature review. J Child Neurol 2020;35:844-851. 
72. Martinelli D, Arceri S, Tronconi L, Tassorelli C. Chronic migraine and Botulinum Toxin Type A: Where do paths cross? Toxicon 2020;178:69-76. 
73. Sohita D. Zavegepant: First Approval, Drugs 2023; 83: 825– 831 
74. Dong G, Kjærgaard NA, Shakibfar S, Sessa M. Ubrogepant and rimegepant: Systematic review, meta-analysis, and meta-regression of clinical studies. Expert Opin Drug Saf 2023;22:59-70. 
75. Claudio T, Francesco C, Maria AG. New Therapeutic Options for Migraine 2023; 29:1964-1966. 
76. Hay DL, Walker CS, Harris PWR. Atogepant (Qulipta) for migraine prevention. Trends Pharmacol Sci 2022; 43:701-702. 
77. Van Der Arend BWH, Van Veelen N, De Ruijter JET, Olsen MH, MaassenVanDenBrink A, Terwindt GM. Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine. Front Neurol 2024;15:1387044. 
78. Frank F, Ulmer H, Sidoroff V, Broessner G. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. Cephalalgia 2021;4:1222-1239.
79.  Tanaka M,  Tuka B,  Vécse L. Navigating the Neurobiology of Migraine: From Pathways to Potential Therapies. Cells 2024; 13:1098-1110. 
80. Tundisi LL, Ataide JA, Costa JSR, de Freitas Coêlho D, Liszbinski RB, Lopes AM, et al. Nanotechnology as a tool to overcome macromolecules delivery issues. Colloids and Surfaces B: Biointerfaces 2023;222:113043. 
81. Yaqoob SB, Adnan R, Rameez Khan RM, Rashid M. Gold, silver, and palladium nanoparticles: a chemical tool for biomedical applications. Front Chem 2020;8:376-390. 
82. Alebooye LF, Hafezi GZ, Alibolandi M, Ebrahimian M, Hashemi M. Evaluation of the effect of crocetin on antitumor activity of doxorubicin encapsulated in PLGA nanoparticles. Nanomed J 2016; 3:23-34. 
83. Saeed M, Sadr S, Gharib A, Lotfalizadeh N, Hajjafari A, Simab PA, et al. Phytosomes: A promising nanocarrier for enhanced delivery of herbal compounds in cancer therapy. J Lab Anim Res 2022;1:26-32. 
84. Leon L, Chung EJ, Rinaldi C. A brief history of nanotechnology and introduction to nanoparticles for biomedical applications. Nanoparticles for biomedical applications: Elsevier; 2020. 1-4. 
85. Sim S, Wong NK. Nanotechnology and its use in imaging and drug delivery. Biomed Rep 2021;14:1-9. 
86. Sahu T, Ratre YK, Chauhan S, Bhaskar L, Nair MP, Verma HK. Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. J Drug Deliv Sci Technol 2021;63:102487. 
87. Gottardo S, Mech A, Drbohlavová J, Małyska A, Bøwadt S, Sintes JR, et al. Towards safe and sustainable innovation in nanotechnology: State-of-play for smart nanomaterials. NanoImpact 2021;21:100297. 
88. Safavinia A, Dehestani S, Salmasi Z, Kalalinia F, Etemad L, Hashemi M. Recent advances in nanocarriers containing Bromelain: In vitro and in vivo studies. Nanomed J 2023;10: 163- 170. 
89. Shahgordi S, Oroojalian F, Hashemi E, Hashemi M. Recent advances in development of nano-carriers for immunogene therapy in various complex disorders. Iran J Basic Med Sci 2022;25:134-147. 
90. Pramanik PKD, Solanki A, Debnath A, Nayyar A, El- Sappagh S, Kwak K-S. Advancing modern healthcare with nanotechnology, nanobiosensors, and internet of nano things: Taxonomies, applications, architecture, and challenges. IEEE Access 2020;8:65230-65266. 
91. Negahdari R, Bohlouli S, Sharifi S, Maleki Dizaj S, Rahbar Saadat Y, Khezri K, et al. Therapeutic benefits of rutin and its nanoformulations. Phytother Res 2021;35:1719-1738. 
92. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res Pharmaceut Sci 2018;13:288-303. 
93. Jamkhande PG, Ghule NW, Bamer AH, Kalaskar MG. Metal nanoparticles synthesis: An overview on methods of preparation, advantages and disadvantages, and applications. J Drug Deliv Sci Technol 2019;53:101174. 
94. Natarajan JV, Nugraha C, Ng XW, Venkatraman S. Sustained-release from nanocarriers: A review. J Control Release 2014;193:122-138. 
95. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based nanoparticles. Heliyon 2022; 8: e08674. 
96. Jayant RD, Atluri VS, Agudelo M, Sagar V, Kaushik A, Nair M. Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomed 2015;1077-1093. 
97. Khan AR, Yang X, Fu M, Zhai G. Recent progress of drug nanoformulations targeting to brain. J Control Release 2018;291:37-64. 
98. Agrahari V, Burnouf P-A, Burnouf T, Agrahari V. Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. Adv Drug Deliv Rev 2019;148:146-180.
99. Kumari S, Goyal A, Sönmez Gürer E, Algın Yapar E, Garg M, Sood M, et al. Bioactive loaded novel nano-formulations for targeted drug delivery and their therapeutic potential. Pharmaceutics 2022;14:1091-1117.
100. Hema S, Thambiraj S, Shankaran DR. Nanoformulations for targeted drug delivery to prostate cancer: An overview. J Nanosci Nanotechnol 2018;18:5171-1591. 
101. Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol 2022;20:395-419.    
102. Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Patel RJ, et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release 2020;321:372-415. 
103. Maher R, Moreno-Borrallo A, Jindal D, Mai BT, Ruiz- Hernandez E, Harkin A. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics 2023;15:746-773. 
104. Nguyen TT, Nguyen TTD, Tran N-M-A, Van Vo G. Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders. Neurochem Res 2022; 47:552-573. 
105. Deepika D, Dewangan HK, Maurya L, Singh S. Intranasal drug delivery of Frovatriptan succinate–loaded polymeric nanoparticles for brain targeting. J Pharmaceut Sci 2019;108:851-859. 
106. Girotra P, Singh SK, Kumar G. Development of zolmitriptan loaded PLGA/poloxamer nanoparticles for migraine using quality by design approach. Int J Biolog Macromol 2016;85:92-101. 
107. Dali P, Shende P. Self-assembled lipid polymer hybrid nanoparticles using combinational drugs for migraine via intranasal route. AAPS PharmSciTech 2022;24:20. 
108. Bhanushali R, Gatne M, Gaikwad R, Bajaj A, Morde M. Nanoemulsion based intranasal delivery of antimigraine drugs for nose to brain targeting. Indian J Pharmaceut Sci 2009;71:707-709. 
109. Harjot K, AM John N. Nanoemulsion for migraine prophylaxis nasal drug delivery: preparation, characterization and in vitro evaluation. Pharmaceut Nanotechnol 2016;4:229-241. 
110. AMJ N, Harjot K. Flunarizine dihydrochloride nanoemulsion for migraine nasal drug delivery: fabrication, characterization and in vitro study. Drug Deliv Let 2016;6:104-112. 
111. Divanbeigi N, Yousefian M, Etemad L, Azizi M, Ebrahimzadeh A, Oroojalian F, et al. Improving the anticancer efficiency of doxorubicin by luteolin nanoemulsion: In vitro study. Nanomed J 2023;10:47-58. 
112. Abdou EM, Kandil SM, El Miniawy HM. Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion. Int J Pharmaceut 2017;529:667-677. 
113. Honarvar NM, Soveid N, Abdolahi M, Djalali M, Hatami M, Karzar NH. Anti-neuroinflammatory properties of n-3 fatty acids and nano-curcumin on migraine patients from cellular to clinical insight: a randomized, double-blind and placebo-controlled trial. Endocrine Metab Immun Dis Drug Target 2021;21:365-373. 
114. Bulboacă AE, Bolboacă SD, Bulboacă AC, Porfire AS, Tefas LR, Suciu ŞM, et al. Liposomal curcumin enhances the effect of naproxen in a rat model of migraine. Med Sci Monit 2019; 25: 5087–5097. 
115. Abdolahi M, Jafarieh A, Sarraf P, Sedighiyan M, Yousefi A, Tafakhori A, et al. The neuromodulatory effects of ω-3 fatty acids and nano-curcumin on the COX-2/iNOS network in migraines: A clinical trial study from gene expression to clinical symptoms. Endocrine Metab Immun Dis Drug Target 2019;19:874-884. 
116. Jha S, Mishra D. Evaluation of brain targeting potential of zolmitriptan mucoadhesive nanoparticles for intranasal drug delivery. Pharmaceut Nanotechnol 2022;10:113-124. 
117. Khezri FANZ, Lakshmi C, Bukka R, Nidhi M, Nargund SL. Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method. Int J Biolog Macromol 2020;142:52-62. 
118. Kataria I, Shende P. Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management. Chem Physic Lipid 2022;243: 105177. 
119. Mandlik SK, Ranpise NS, Mohanty BS, Chaudhari PR. A coupled bimodal SPECT-CT imaging and brain kinetics studies of zolmitriptan-encapsulated nanostructured polymeric carriers. Drug Deliv Translat Res 2018;8:797-805. 
120. Mohamed MI, Abdelbary AA, Kandil SM, Mahmoud TM. Preparation and evaluation of optimized zolmitriptan niosomal emulgel. Drug Develop Industr Pharm 2019;45:1157-1167. 
121. Jain R, Nabar S, Dandekar P, Patravale V. Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharmaceut Res 2010;27:655-664. 
122. Awadeen RH, Boughdady MF, Meshali MM. Quality by design approach for preparation of zolmitriptan/chitosan nanostructured lipid carrier particles–formulation and pharmacodynamic assessment. Int J Nanomed 2020:8553-8568. 
123. Hassan DH, Shohdy JN, El-Setouhy DA, El-Nabarawi M, Naguib MJ. Compritol-based nanostrucutured lipid carriers (NLCs) for augmentation of zolmitriptan bioavailability via the transdermal route: In vitro optimization, ex vivo permeation, in vivo pharmacokinetic study. Pharmaceutics 2022;14:1484-1505. 
124. Abd El-Halim SM, Mamdouh MA, Eid SM, Ibrahim BM, Aly Labib DA, Soliman SM. The potential synergistic activity of zolmitriptan combined in new self-nanoemulsifying drug delivery systems: Atr-ftir real-time fast dissolution monitoring and pharmacodynamic assessment. Int J Nanomed 2021:6395-412. 
125. Shelke S, Shahi S, Jalalpure S, Dhamecha D. Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: Formulation, optimization, evaluation and permeation studies. J Liposome Res 2016;26:313-323. 
126. Hansraj GP, Singh SK, Kumar P. Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential. Int J Biolog Macromol 2015;81:467-476. 
127. Patravale VB, Upadhaya PG, Jain RD. Preparation and characterization of micelles. Methods Mol Biol 2019; 2000:19-29.
128. Masjedi M, Azadi A, Heidari R, Mohammadi-Samani S. Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. J Pharm Pharmacol 2020;72:1341- 1351. 
129. Assadpour S, Akhtari J, Shiran MR. Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine. Caspian J Inter Med 2022;13:90-99. 
130. Yadav RK, Shah K, Dewangan HK. Intranasal drug delivery of sumatriptan succinate-loaded polymeric solid lipid nanoparticles for brain targeting. Drug Develop Industr Pharm 2022;48:21-28. 
131. Girotra P, Singh SK. A comparative study of orally delivered PBCA and ApoE coupled BSA nanoparticles for brain targeting of sumatriptan succinate in therapeutic management of migraine. Pharmaceut Res 2016;33:1682-1695. 
132. Bulboacă AE, Bolboacă SD, Stănescu IC, Sfrângeu CA, Porfire A, Tefas L, et al. The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats. Int J Nanomed 2018:3093-3103.
133. Ribeiro LN, Rodrigues da Silva GH, Couto VM, Castro SR, Breitkreitz MC, Martinez CS, et al. Functional hybrid nanoemulsions for sumatriptan intranasal delivery. Front Chem 2020;8:589503.
134. Berah R, Ghorbani M, Moghadamnia AA. Synthesis of a smart pH-responsive magnetic nanocomposite as high loading carrier of pharmaceutical agents. Int J Biolog Macromol 2017;99:731-738. 
135. Girotra P, Thakur A, Kumar A, Singh S.K. Identification of multi-targeted anti-migraine potential of nystatin and development of its brain targeted chitosan nanoformulation. Int J Boil Macromol 2017;96:687–696.
136. Neha Gulati N, Upendra Nagaich U, Saraf SA. Intranasal delivery of chitosan nanoparticles for migraine therapy. Sci Pharm 2013; 81:843-854. 
137. Abou Youssef NAH, Kassem AA, Farid RM, Ismail FA, Magda Abd Elsamea E-M, Boraie NA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. Int J Pharmaceut 2018;548:609-624. 
138. Salem LH, El-Feky GS, Fahmy RH, El Gazayerly ON, Abdelbary A. Coated lipidic nanoparticles as a new strategy for enhancing nose-to-brain delivery of a hydrophilic drug molecule. J Pharmaceut Sci 2020;109:2237-2251. 
139. Abo El-Enin HA, Mostafa RE, Ahmed MF, Naguib IA, A. Abdelgawad M, Ghoneim MM, et al. Assessment of nasal-brain-targeting efficiency of new developed mucoadhesive emulsomes encapsulating an anti-migraine drug for effective treatment of one of the major psychiatric disorders symptoms. Pharmaceut 2022;14:410-427.
140. Girotra P, Singh SK. Multivariate optimization of rizatriptan benzoate-loaded solid lipid nanoparticles for brain targeting and migraine management. AAPS PharmSciTech 2017;18:517-528. 
141. Dali P, Shende P. Use of 3D applicator for intranasal microneedle arrays for combinational therapy in migraine. Int J Pharmaceut 2023;635:122714. 
142. Ita K, Ukaoma M. Progress in the transdermal delivery of antimigraine drugs. J Drug Deliv Sci Technol 2022;68:103064. 
143. Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int J Pharmaceut 2019;565:258-268. 
144. Puri V, Nagpal M, Singh I, Singh M, Dhingra GA, Huanbutta K, et al. A comprehensive review on nutraceuticals: therapy support and formulation challenges. Nutrients 2022;14:4637-4664. 
145. Chaurasiya S, Kulhari H. Essential Considerations for Brain Delivery of Nanoformulations. Drug Delivery Strategies in Neurological Disorders: Challenges and Opportunities: Springer; 2024. 251-269. 
146. Chattopadhyay S, Das S, Sarma KN. Nose-to-brain drug delivery: An update to the alternative path to successful targeted antimigraine drugs. Int J Appl Pharm 2021;13:67-75. 
147. Bahadur S, Pathak K. Challenges in Targeting Nasal Passage and Nose-to-Brain Delivery via Nanoemulsions. Nasal Drug Delivery: Formulations, Developments, Challenges, and Solutions 2023:59-82. 
148. Bhunia S, Kolishetti N, Vashist A, Yndart Arias A, Brooks D, Nair M. Drug delivery to the brain: recent advances and unmet challenges. Pharmaceutics 2023;15:2658-2682.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 1
January 2025
Pages 16-30

Files

Share

How to cite

Statistics